INTRODUCTION
Approximately 1.5 million American have been diagnosed with infl ammatory bowel disease (IBD), a chronic relapsing and remitting disorder of the gastrointestinal tract ( 1 ) . For patients with moderate to severe disease, anti-tumor necrosis factors (antiTNFs) such as certolizumab and adalimumab are more eff ective than oral immunosuppression for disease control (2) (3) (4) (5) (6) . However, while these medications are initially eff ective in more than 50% of patients, ~1/3 of patients lose response over time ( 7 ) . One of signifi cant predictor of the development of antibodies ( 11 ) . Yet, to date, little is known about the threshold of adherence necessary to avoid fl ares associated with steroid use and hospitalizations. Historically, possession of medication for >80% of the intended time of use has been considered acceptable adherence ( 12, 13 ) and used as a target in adherence studies. However, due to the risk of auto-antibody formation, this may not apply to anti-TNFs. We hypothesized that a higher adherence threshold is necessary for these medications due to threat of antibody formation with intermittent use and that lower adherence is associated with increased risk of disease fl ares.
To address this gap in knowledge, we measured the adherence rates to subcutaneously delivered biologics from 2009 to 2013 among enrollees with IBD in a large health insurance claims database. We aimed to identify an optimal adherence threshold for these medications to prevent important clinical outcomes like steroid use and new hospitalizations based on medication possession ratio, determine the eff ect of non-adherence below this threshold on these outcomes using survival analysis, and identify other predictors of poor outcomes including concomitant medication use and costs of medications.
METHODS

Data source
We studied the medication refill patterns of patients identified to have IBD from the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013. This large administrative database is derived from data from insurance coverage of enrollees who are covered by large employers in the United States. The database covers inpatient and out patient visits in addition to pharmacy claims data on ~50 million people.
Cohort
Individuals were defi ned as having IBD based on the presence of a single inpatient encounter or two outpatient claims on different days with an ICD-9CM code of Crohn's (555.x) or ulcerative colitis (556.x). Patients were excluded if they did not have at least 12 months of continuous coverage with pharmacy benefi ts. When patients had multiple periods of coverage, only the most recent coverage period was examined to ensure that relevant outcomes were captured. Th e diagnosis of Crohn's or ulcerative colitis was assigned if all the ICD9-CM codes were concordant with that diagnosis. In instances which this threshold was not met, the patient was given a diagnosis based on the majority of the most recent nine ICD-9 codes. Th e same rule applies to patients with less than nine ICD-9 codes; however, patients with equal number of ICD-9 codes were labeled as having indeterminate colitis ( 14 ) . CZP users with an ulcerative colitis diagnosis were excluded from the study as CZP is not approved for ulcerative colitis.
Pharmaceutical claims were analyzed for dispenses of both adalimumab and certolizumab. Errant claims identifi ed as those indicating that a quantity of zero or less was dispensed were excluded from analysis. Claims data that indicated that unusual quantities of medication were dispensed was also deleted. For adalimumab, we expected to fi nd no more than six syringes dispensed in 14 days during induction (ratio of 2.33 days/injection) and no less than two syringes dispensed in 30 days for maintenance (ratio of 15 days/injection). For certolizumab, we expected to fi nd no more than two kits dispensed in 14 days during induction (ratio of 7 days/kit) and no less than one kit dispensed for a 30-day period during maintenance (ratio of 30 days/kit). Analysis of each medication was limited to those patients who were exposed to the fi rst anti-TNF during the study time period. Concomitant medication use at the time of the fi rst anti-TNF was defi ned by a concomitant medication course starting before the fi rst anti-TNF date and ending aft er that date. Concomitant drug courses allow for a maximum 14 day gap between prescriptions of the same drug class.
A medication possession ratio (MPR) was used to assess anti-TNF adherence. Th e medication possession ratio is calculated as (sum of the days of medication supplied)/(the sum of the days in the total refi ll intervals) ( 15 ) . For example, if a patient is dispensed a 28 day supply on 1 January and then another 28 day supply on 1 February, the MPR is calculated as 56/59 or 0.95. Courses were classifi ed as the prescription of an individual anti-TNF with no greater than 120 days between doses administered. Only the fi rst course for each medication was analyzed in order to limit the eff ect of repeated starts and stops on medication effi cacy and outcomes. Courses with an MPR above the 99th percentile (MPR>1.4) were deleted as possible outliers. Th ese were suspected to contain errant claims data. MPR was therefore capped at 1.4. An average payment per injection/kit was calculated for each course using the patient copay and deductible data from each claim. Th e optimal MPR cut points were then identifi ed and patients classifi ed into adherent vs. non-adherent groups accordingly. In order to determine if medication side eff ects were the reason behind medication non-adherence or discontinuation we compared medication related side eff ect frequencies (pneumonia, psoriasis/rash, lupus, and infection) between the adherent and non-adherent cohort. Th e ICD-9CM codes used for these side eff ects are presented in Supplementary Data online. We also determined the percentage of patients who experienced anti-TNF escalation before discontinuation. To achieve this, we compared prescriptions at the beginning and end of the maintenance period and identifi ed any increase in dosage.
Statistical analysis
Th e statistical analyses were performed using SAS 9.4 (Cary, NC). Continuous variables were analyzed with the Mann-Whitney U test. Categorical variables were analyzed with the χ 2 test. Th e relationship between MPR and adverse outcomes (hospitalization or fi rst corticosteroid use) was examined using Cox proportional hazard models taking into consideration time-to-event. MPR was initially included as a continuous variable. Only events that occurred within 120 days of the last fi ll were counted since it was assumed that events that occurred later were unrelated to the use of these medications. In order to identify an optimal cutoff for MPR, the fi ndcut macro was utilized ( 16 ) ( 17 ) . Th is method has been used in a number of studies to identify cutoff s in continuous variables in survival analysis ( 18, 19 ) . It involves calculating all the log-rank statistic for all possible splits and selecting the optimal cutpoint based on maximizing the log-rank statistic. Th is is the point which maximally separates patients above and below the point with regards to outcomes. A sensitivity analysis was also conducted to examine the change in multivariable hazard of an outcome by varying the cutoff . Hospitalization or corticosteroid initiation within 90-days of initiation were not counted as events. Short, individual courses (<14 days with no subsequent prescriptions) of steroids were also excluded as events. Patients who were not hospitalized or prescribed steroids were censored at the last day of their last prescription fi ll.
RESULTS
From 2009 to 2013, 22,285 Individuals with IBD were prescribed an anti-TNF. Of these patients, 55% were female, average age was 41.7 years (±14.9) and 80.6% had Crohn's disease. Of these individuals, 90.7% received one anti-TNF type during the study period, 9.1% received two anti-TNF types and just 0.2% were prescribed three anti-TNFs.
Adalimumab
During the study period, 17,988 patients were prescribed adalimumab. Aft er applying exclusion criteria, 6,937 were prescribed adalimumab as their only anti-TNF, and 5,325 were given at least 3 months supply without other errant fi ll data. Th e primary outcome of hospitalization or new steroid prescription was met in 1,725 (32.4%), and 14.8% were on steroids at initiation of adalimumab ( Table 1 ). Only 15.2% of the cohort were on an immunomodulator at the time of anti-TNF initiation while 10.6% were using narcotics.
Th e mean cumulative MPR for adalimumab was 0.94 (±0.13). In bivariate analyses, the cumulative MPR was signifi cantly associated with either hospitalization or a new steroid prescription. Using the Contal-O'Quigley method to examine the cumulative MPR, a cutoff of 0.86 created the greatest diff erence in outcomes between non-adherent and adherent patients (HR 0.71, 95%CI: 0.64-0.79, P <0.01). Using this cutoff , 20.5%, were classifi ed as non-adherent. Th e time to outcome was statistically signifi cant between adherent patients with an MPR of at least 0.86 and those below 0.86 ( Figure  1 a ) . A small but statistically signifi cant diff erence in median copay was found ( P =0.04) between patients who were adherent ($43. Multivariable analysis of the eff ect of adherence using a cumulative MPR threshold of 0.86 found that adherent patients were less likely to be hospitalized or to be given a new steroid prescription (HR 0.75, 95%CI: 0.67-0.83, P <0.001), aft er adjusting for age, gender, and concomitant medication use at initiation of anti-TNF. Narcotic use at anti-TNF initiation was associated with future hospitalization or steroid prescription (HR 1.57, 95%CI: 1.37-1.81, P <0.001).
No diff erence in infection and medication related side eff ects was found between adherent and non-adherent patients during the period of anti-TNF use ( Table 2 ). In addition, non-adherent patients did not experience higher proportion of escalation compared with adherent patients (16.6 vs. 14.2%).
Th e sensitivity analysis of varying cutpoints of MPRs in a multivariable model is presented in Table 3 . Th e benefi cial eff ects of increased adherence continue with MPRs up to 0.97 at which point there does not appear to be a signifi cant improvement in outcomes above and below this cutoff (plateau point).
Certolizumab
Th ere were 4,241 individuals prescribed certolizumab during the study period. Of these, 1,221 were prescribed the drug as the only anti-TNF with at least 6 months of coverage prior to drug initiation and at least 6 months of coverage aft er initiation. Aft er removing patients with errant data, multiple courses of the drug, and less than three fi lls, there were 723 patients remaining in the cohort. Among these patients, 269 (37.2%) had a hospitalization or new steroid prescription more than 90 days aft er fi rst starting the medication, and 9.7% were on steroids at the time of anti-TNF initiation.
Th e average cumulative MPR was 0.87 (±0.14), with 14.7% of the cohort with an MPR of 1.0 or higher. Selecting an MPR of 0.87 as the cutoff was identifi ed as having the greatest diff erence between adherent and non-adherent groups based on the Contal and O'Quigley method. Using this as the adherence threshold, 43.7% of the cohort was non-adherent. Th ere was a signifi cant difference in time to hospitalization or new steroid prescription based on this adherence threshold ( Figure 1 b ) . Th e median copayment was similar ( P =0. In bivariate analyses, the hazard ratio of hospitalization or new steroid prescription was 0.54 (95%CI: 0.42-0.69, P <0.01) ( Table 5 ). In the multivariable model, narcotic use remained associated with an increased risk of hospitalization or new steroid use. Non-adherent patients did not experience increased medication related side eff ects or infections during the period of anti-TNF use compared with adherent patients ( Table 2 ) . Similarly, no increased escalation proportion was found in non-adherent patients compared with those who were adherent (6.0 vs. 7.6%).
Th e sensitivity analysis of varying cutpoints of adherence for certolizumab found that increasing adherence up to an MPR of 0.95 was benefi cial (plateau point). Patients with an MPR of 0.95 or greater did not have a reduction in adverse outcomes compared to those below this threshold.
DISCUSSION
Using the classic MPR benchmark for adherence of 0.8, the patients in our cohort taking anti-TNFs would be considered adherent, with only 13.5% of patients taking adalimumab and 25.6% of those taking certolizumab falling below this level. In this study of an administrative database, we found that an MPR of 0.87 or higher is associated with a signifi cantly lower risk or hospitalization or new steroid prescription for those initiating certolizumab and an MPR of 0.86 or higher for those starting adalimumab. Th ese adherence measures equate to missing only 4 days of medication in a 28 day cycle. Th ese fi ndings confi rm our to be higher in patients with certolizumab and that those who are non-adherent have more infl ammation and consequently, worse clinical outcomes ( 26 ) .
Our analysis identifi ed an MPR cutoff that created the greatest diff erence in outcomes above and below the cutoff . A number of studies across a range of disease states have arbitrarily set the adherence threshold at 0.8 in defi ning adherence ( 13, 27 ) . Others have identifi ed that adherence above this level is benefi cial in reducing hospitalizations or achieving clinical targets (28) (29) (30) (31) . We have identifi ed a cutoff for adherence based on one method of selecting thresholds, in order to maximize the diff erence in outcomes between adherent and non-adherent patients. We also examined increasing MPR thresholds and found that MPRs up to 0.95-0.97 lead to improved outcomes. At MPRs over this plateau point, there did not appear to be diff erence in outcomes compared to those patients who did not meet this cutoff . An adherence level of 0.87 corresponds to missed or delayed dosing by only 4 days per month on average. Th is may be particularly problematic for these medications as they are given relatively infrequently, every 2 or 4 weeks, and in many instances have to be obtained from a specialty pharmacy by mail. Prior authorizations, annual renewals, delays in fi lling prescriptions, and holidays frequently lead to delayed or missed doses. Our fi ndings suggest that these medications, like antiretrovirals for HIV ( 32 ) and antivirals for hepatitis C ( 31 ), require exceptionally high levels of adherence. Interventions to help IBD patients achieve and maintain these high levels hypothesis that adherence targets for these medications should be set higher than traditional medications and establish the relationship between non-adherence and disease fl ares.
Our study is unique in that it is the largest study of adherence to biologics among IBD patients specifi cally and examined the eff ects of non-adherence on downstream consequences such as hospitalizations and steroid use. Another analysis of adalimumab use for all indications found an average MPR of 0.84 ( 20 ) , lower than the average MPR we found here for adalimumab for IBD alone: 0.94. A small percentage of the patients in the comparison study had Medicare or Medicaid, both of which have been associated with lower adherence than private insurance ( 21 ) . It is also possible that patients who take adalimumab for IBD may be more adherent than patients who take this drug for other indications. We found no meaningful relationship between patient costs and adherence for the two drugs studied. Consistent with our fi ndings, Goldman et al. found no association between patient costs and adherence for specialty drugs in autoimmune conditions; they speculate that cost is not an issue once patients are placed on biologics because these patients' other costs are so high and deductible reached rapidly ( 22 ) . Other studies, however, have revealed a relationship between patient costs and patient adherence in other disease states (23) (24) (25) .
Th e adherence results for the two biologics are notably diff erent with lower adherence among patients taking certolizumab compared to adalimumab. Th e dosing of certolizumab is less frequent than adalimumab which may infl uence the benefi t of developing routines on adherence. Adalimumab is available as an injector pen while certolizumab is not; this may infl uence patients' adherence either through diff erences in pain with administration or ease of administration. Th ere also maybe diff erences in the copay assistance programs which led to diff erences in adherence between ADA and CZP. It is also notable that while the MPR cutoff identifi ed for these two drugs was similar, the association between nonadherence and rate of hospitalization or steroid use was stronger for those taking certolizumab. We speculate that drug levels have 
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Optimal Threshold of Adherence for Anti-TNFs of adherence are essential to the long-term success of, and deriving the most value from these expensive medications. Th e limitations to our study are related to the shortcomings of using an administrative database. We cannot account for valid reasons for skipping or missing medications such as bacterial infections or injection reactions. Patients may be instructed to skip medication doses during lower respiratory tract infections or other infections. Th e downstream eff ect of skipping these doses however is still notable in that it leads to higher risk of hospitalization or steroid use for IBD. However, we noticed no increase in infections and medication related side eff ects between the adherent and non-adherent groups. Our analysis cannot adjust for other important factors including smoking or disease severity which are known to infl uence the eff ectiveness of these medications. Th e use of an administrative database limits our assessment of adherence to an indirect measure like MPR which may not truly account for patient adherence. Additionally, errant data were excluded in the MPR calculation which may limit generalizability. AntiTNFs, however, are unlikely to be obtained and then not used in a repeated fashion due to their cost. Our study encompasses the time period just before and aft er the landmark study showing dual therapy to be superior to monotherapy ( 2 ) and only a small percentage of biologic users were on an immunomodulator at the time of initiation. Dual therapy is known to reduce the risk of anti-drug antibodies and prolong drug use. It is possible that future studies may show diff erences in outcomes among adherent patients to biologics if taking (and adherent) to immunomodulators. Finally, our estimates of adherence to anti-TNFs may not refl ect the true estimates of adherence nationally since the data source includes only patients with commercial insurance only and does not sample those with Medicare or Medicaid or no insurance coverage.
In conclusion, we have identifi ed an association between adherence to subcutaneous biologics and hospitalizations and steroid use. We show that adherence levels should be maximized for these medications, ideally above an MPR of 0.87, with a plateau point of 0.95-0.97, to prevent poor outcomes. Th e adherence threshold of 0.87 allows for less than 4 days of missed medication per 28 day period. Future work on the most eff ective interventions targeted to high-risk patients taking these medications who fall below this level of adherence is necessary. 
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